Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments

CMTM6 EMT GBM migration piperlonguminine

Journal

Frontiers in molecular neuroscience
ISSN: 1662-5099
Titre abrégé: Front Mol Neurosci
Pays: Switzerland
ID NLM: 101477914

Informations de publication

Date de publication:
2022
Historique:
received: 24 08 2022
accepted: 16 12 2022
entrez: 26 1 2023
pubmed: 27 1 2023
medline: 27 1 2023
Statut: epublish

Résumé

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain containing 6 (CMTM6) is a protein localized to the cell membrane and is known for its ability to co-localize with PD-L1 on the plasma membrane, prevent PD-L1 degradation, and maintain PD-L1 expression on the cell membrane. CMTM6 is highly expressed and plays an important role in various tumors such as oral squamous cell carcinoma (OSCC) and colorectal cancer (CRC), however, its role in Glioblastoma multiforme (GBM) is unclear. In this paper, to investigate the role of CMTM6 in GBM, we analyzed the expression of CMTM6 in GBM, the interaction with CMTM6 and the associated genes by bioinformatics. Importantly, we analyzed the expression of CMTM6 in GBM in relation to tumor-infiltrating lymphocytes (TILs), immunoinhibitors, immunostimulators, chemokines and chemokine receptors. We further analyzed the function of CMTM6 and performed The results showed that CMTM6 was highly expressed in GBM and correlated with multiple genes. Furthermore, CMTM6 is closely related to the immune microenvironment and inflammatory response in GBM. Bioinformatic analysis of CMTM6 correlated with the function of GBM, and our experiments demonstrated that CMTM6 significantly promoted the migration of GBM cells and epithelial-mesenchymal transition (EMT), but had no significant effect on other functions. Interestingly, we found that in GBM, PL promotes the expression of CMTM6. In this paper, we have performed a detailed analysis and validation of the role of CMTM6 in GBM using bioinformatics analysis and in vitro experiments to demonstrate that CMTM6 may be a potential target for glioma therapy.

Identifiants

pubmed: 36698778
doi: 10.3389/fnmol.2022.1026927
pmc: PMC9869805
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1026927

Informations de copyright

Copyright © 2023 Meng, Li, Li, Wang, Wang and Qu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Oxid Med Cell Longev. 2014;2014:653732
pubmed: 24967005
Front Mol Biosci. 2022 Jan 31;9:769032
pubmed: 35174213
Cancer Immunol Immunother. 2021 Feb;70(2):417-429
pubmed: 32770259
Cancer Immunol Immunother. 2022 Oct;71(10):2325-2340
pubmed: 35294592
Oncoimmunology. 2020 Dec 29;10(1):1864909
pubmed: 33457084
Oncoimmunology. 2022 Jan 5;11(1):2011673
pubmed: 35024247
Cancer Immunol Immunother. 2021 Apr;70(4):1015-1029
pubmed: 33104837
Int Immunopharmacol. 2020 Jun;83:106478
pubmed: 32278132
Cancer Sci. 2021 Aug;112(8):3314-3323
pubmed: 34080242
J Cancer Res Clin Oncol. 2022 Jan;148(1):47-56
pubmed: 34783871
Cell Death Dis. 2022 Mar 19;13(3):251
pubmed: 35304440
Nature. 2017 Sep 7;549(7670):101-105
pubmed: 28813417
Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Aug;132(2):202-209
pubmed: 34034998
Front Oncol. 2021 Jan 20;10:585961
pubmed: 33552963
Cancer Cell Int. 2021 Jan 28;21(1):78
pubmed: 33509216
J Transl Med. 2021 Mar 23;19(1):120
pubmed: 33757532
DNA Cell Biol. 2020 Oct 21;:
pubmed: 33090010
Hepatol Commun. 2020 Nov 24;5(2):334-348
pubmed: 33553979
Nature. 2017 Sep 7;549(7670):106-110
pubmed: 28813410
Ann Transl Med. 2021 Jan;9(2):131
pubmed: 33569433
JCI Insight. 2021 Feb 22;6(4):
pubmed: 33434185
Int Immunopharmacol. 2020 Nov;88:106864
pubmed: 32866782
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680324
Neurotherapeutics. 2017 Apr;14(2):372-384
pubmed: 28374184
Am J Cancer Res. 2019 Jun 01;9(6):1161-1171
pubmed: 31285949
Cancer Immunol Res. 2020 Feb;8(2):179-191
pubmed: 31771985
Biochem Biophys Res Commun. 2013 Jul 19;437(1):87-93
pubmed: 23796709
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33579737

Auteurs

Haining Meng (H)

Department of Emergency Medicine, Medical College of Qingdao University, Qingdao, Shandong, China.
Department of Intensive Care Unit, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, Shandong, China.

Shaohua Li (S)

Department of Laboratory Medicine, The Third People's Hospital of Qingdao, Qingdao, Shandong, China.

Qingshu Li (Q)

Department of Intensive Care Unit, Qingdao Municipal Hospital, Qingdao, Shandong, China.

Yuqin Wang (Y)

Department of Emergency, Qingdao Municipal Hospital, Qingdao, Shandong, China.

Guoan Wang (G)

Qingdao Municipal Hospital, Qingdao, Shandong, China.

Yan Qu (Y)

Department of Intensive Care Unit, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao, Shandong, China.

Classifications MeSH